AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36698862 — intervention group
Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) alone
Number of subjects: 87
Study 36698862 — intervention group
Group type: COMPARATOR
Intervention: Sound stimulation alone
Number of subjects: 87
Study 36698880 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyflow module of the Ansys software
Number of subjects: 45
Study 36699018 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS and central obesity
Number of subjects: 166
Study 36699018 — intervention group
Group type: COMPARATOR
Intervention: Women without PCOS
Number of subjects: 166
Study 36699304 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-based deferred cord clamping (PBCC) after the onset of stable regular breathing
Number of subjects: 71
Study 36699304 — intervention group
Group type: COMPARATOR
Intervention: Standard time-based cord clamping < 1 minute (control group)
Number of subjects: 71
Study 36699521 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional MRI (rs-fMRI) metrics including fractional amplitude of low-frequency fluctuation (fALFF), regional homogeneity (ReHo), degree centrality (DC), voxel-mirrored homotopic connectivity (VMHC), functional connectivity strength (FCS), and seed-based FC.
Number of subjects: 100
Study 36699521 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 100
Study 36699896 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Sexual Harassment intervention
Number of subjects: 0
Study 36700062 — intervention group
Group type: EXPERIMENTAL
Intervention: BELA+EVL
Number of subjects: 68
Study 36700062 — intervention group
Group type: COMPARATOR
Intervention: TAC+MMF
Number of subjects: 68
Study 36700361 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Tour Group (VT+)
Number of subjects: 125
Study 36700361 — intervention group
Group type: COMPARATOR
Intervention: Non-virtual Tour Group (VT-)
Number of subjects: 125
Study 36700391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Staging System (DSS)
Number of subjects: 0
Study 36700426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 6264
Study 36700426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with QRS ≥150 ms and LBBB
Number of subjects: 6264
Study 36700426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with QRS ≥150 ms and IVCD
Number of subjects: 6264
Study 36700426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with RBBB
Number of subjects: 6264
Study 36700518 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIG prepared from humans
Number of subjects: 947
Study 36700518 — intervention group
Group type: COMPARATOR
Intervention: hIVIG
Number of subjects: 947
Study 36700518 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 947
Study 36700520 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term prophylactic dose anticoagulation
Number of subjects: 1491
Study 36700520 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapeutic dose oral anticoagulation
Number of subjects: 1491
Study 36700520 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antiplatelet therapy
Number of subjects: 1491
Study 36700520 — intervention group
Group type: COMPARATOR
Intervention: Long-term cilostazol
Number of subjects: 1491
Study 36700571 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program with telecoaching (weekly phone calls from a physiotherapist)
Number of subjects: 42
Study 36700571 — intervention group
Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation program without telecoaching
Number of subjects: 42
Study 36700700 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of poor-grade aSAH after 6 months
Number of subjects: 250
Study 36700700 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of poor-grade aSAH after 12 months
Number of subjects: 250
Study 36700705 — intervention group
Group type: EXPERIMENTAL
Intervention: i-FACTOR
Number of subjects: 220
Study 36700705 — intervention group
Group type: COMPARATOR
Intervention: Local autograft
Number of subjects: 220
Study 36700738 — intervention group
Group type: EXPERIMENTAL
Intervention: Open shunt group (Codman Certas Plus valve set at 4)
Number of subjects: 18
Study 36700738 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (Codman Certas Plus valve set at 8)
Number of subjects: 18
Study 36700738 — intervention group
Group type: EXPERIMENTAL
Intervention: Open shunt group
Number of subjects: 18
Study 36700738 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 18
Study 36700734 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 25 mg once daily
Number of subjects: 13
Study 36700734 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 13
Study 36700734 — intervention group
Group type: COMPARATOR
Intervention: Warfarin and digoxin alone
Number of subjects: 13
Study 36700734 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 13
Study 36700770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 36700770 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 36700853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression changes in fetal brain samples with biallelic pathogenic variants in HEXA
Number of subjects: 0
Study 36700928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiffractive EDOF IOL
Number of subjects: 52
Study 36700928 — intervention group
Group type: COMPARATOR
Intervention: Trifocal IOL
Number of subjects: 52
Study 36701139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU)
Number of subjects: 2259
Study 36701139 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg)
Number of subjects: 2259
Study 36701139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D3 and calcium
Number of subjects: 2259
Study 36701146 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma inflammatory biomarkers (IL-6, sTNF-αR2, hsCRP) in the highest quintile of inflammation
Number of subjects: 1494
Study 36701146 — intervention group
Group type: COMPARATOR
Intervention: Plasma inflammatory biomarkers (IL-6, sTNF-αR2, hsCRP) in the lowest quintile of inflammation
Number of subjects: 1494
Study 36701146 — intervention group
Group type: COMPARATOR
Intervention: Inflammatory biomarkers and celecoxib intervention
Number of subjects: 1494
Study 36701146 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher inflammation after diagnosis
Number of subjects: 1494
Study 36701184 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter pain and indigestion medications
Number of subjects: 273
Study 36701184 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigestion medications
Number of subjects: 273
Study 36701271 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturative stress
Number of subjects: 400
Study 36701271 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 400
Study 36701271 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 400
Study 36701271 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance (mediator)
Number of subjects: 400
Study 36701331 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently enlarged genital hiatus (GH)
Number of subjects: 81
Study 36701331 — intervention group
Group type: COMPARATOR
Intervention: Stably normal GH
Number of subjects: 81
Study 36701401 — intervention group
Group type: COMPARATOR
Intervention: Quitting Immediately (QI)
Number of subjects: 1571
Study 36701401 — intervention group
Group type: COMPARATOR
Intervention: Quitting Progressively (QP)
Number of subjects: 1571
Study 36701531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful yoga intervention (MYI) as add-on to treatment as usual (TAU)
Number of subjects: 171
Study 36701531 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 171
Study 36701604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Number of subjects: 200
Study 36701604 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 200
Study 36701613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 6 or more hours
Number of subjects: 200
Study 36701613 — intervention group
Group type: COMPARATOR
Intervention: Oral intake ('fed') within 2 hours of the test
Number of subjects: 200
Study 36701619 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier-weight polypropylene mesh
Number of subjects: 339
Study 36701619 — intervention group
Group type: COMPARATOR
Intervention: Lightweight polypropylene mesh
Number of subjects: 339
Study 36701620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training using a motion-based digital therapeutic device
Number of subjects: 363
Study 36701620 — intervention group
Group type: COMPARATOR
Intervention: Standard home pelvic floor muscle training program
Number of subjects: 363
Study 36701635 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery expectancy (measured through preoperative survey)
Number of subjects: 174
Study 36701635 — intervention group
Group type: EXPERIMENTAL
Intervention: High recovery expectancy
Number of subjects: 174
Study 36701635 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual recovery (measured at postoperative weeks 2 and 6)
Number of subjects: 174
Study 36701651 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-999 at 1.2 mg/kg every 21 days
Number of subjects: 15
Study 36701651 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-999 at 1.6 mg/kg
Number of subjects: 15
Study 36701651 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-999
Number of subjects: 15
Study 36701676 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy
Number of subjects: 0
Study 36701676 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care not specified)
Number of subjects: 0
Study 36701797 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized acute treatment of migraine
Number of subjects: 0
Study 36701797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib dose escalation over the first 2 weeks (DE1)
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol + loperamide (CL)
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib dose escalation over the first 4 weeks (DE2)
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide + loperamide (BL)
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (L)
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol + loperamide as needed (CL-PRN)
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib with proactive management
Number of subjects: 563
Study 36702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib treatment
Number of subjects: 563
Study 36702138 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF, decitabine, and busulfan-cyclophosphamide conditioning
Number of subjects: 202
Study 36702138 — intervention group
Group type: COMPARATOR
Intervention: busulfan-cyclophosphamide conditioning
Number of subjects: 202
Study 36702146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg every 4 weeks)
Number of subjects: 602
Study 36702146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 36702329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib 60-120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity
Number of subjects: 124
Study 36702499 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgical thalamotomy
Number of subjects: 27
Study 36702566 — intervention group
Group type: EXPERIMENTAL
Intervention: rtCGM with alerts (n=127)
Number of subjects: 254
Study 36702566 — intervention group
Group type: COMPARATOR
Intervention: is-rtCGM (switched from isCGM without alerts to rtCGM with alerts; n=119)
Number of subjects: 254
Study 36702574 — intervention group
Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA) group
Number of subjects: 10491
Study 36702574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10491
Study 36702574 — intervention group
Group type: COMPARATOR
Intervention: Control group (excluding those without recent GP consultation)
Number of subjects: 10491
Study 36702771 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/California/04/2009/H1N1pdm-like virus inoculation
Number of subjects: 76
Study 36702771 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline titers ≥40 by HAI
Number of subjects: 76
Study 36702771 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline titers ≥40 by MN
Number of subjects: 76
Study 36702771 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline titers <40 by HAI
Number of subjects: 76
Study 36702771 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline titers <40 by MN
Number of subjects: 76
Study 36702771 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 2-fold increase in baseline HAI
Number of subjects: 76
Study 36702822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 0
Study 36702822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36702934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir administered intravenously every 8 hours with a 1-hour infusion of 500 mg/m
Number of subjects: 1
Study 36702949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PD-1, BRAF and MEK inhibition
Number of subjects: 0
Study 36703019 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-PRO Plus
Number of subjects: 845
Study 36703025 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ICP waveform analysis
Number of subjects: 0
Study 36703104 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing breastfeeding intervention delivered by a trained lactation consultant in hospital, with continued support for up to 6 months postpartum.
Number of subjects: 0
Study 36703104 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 36703109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based electronic decision-support system (EDSS) used by healthcare providers during ANC visits.
Number of subjects: 1320
Study 36703109 — intervention group
Group type: COMPARATOR
Intervention: Standard of care ANC services without EDSS.
Number of subjects: 1320
Study 36703120 — intervention group
Group type: EXPERIMENTAL
Intervention: ADIVA (advanced double intravenous vasopressor automated system)
Number of subjects: 94
Study 36703120 — intervention group
Group type: COMPARATOR
Intervention: DIVA (double intravenous vasopressor automated system)
Number of subjects: 94
Study 36703120 — intervention group
Group type: EXPERIMENTAL
Intervention: ADIVA
Number of subjects: 94
Study 36703120 — intervention group
Group type: COMPARATOR
Intervention: DIVA
Number of subjects: 94
Study 36703160 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-light front-of-pack environmental label
Number of subjects: 132
Study 36703160 — intervention group
Group type: COMPARATOR
Intervention: No label condition
Number of subjects: 132
Study 36703170 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based CIMT
Number of subjects: 29
Study 36703170 — intervention group
Group type: COMPARATOR
Intervention: Therapist-based CIMT
Number of subjects: 29
Study 36703196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metabolic activators (CMA)
Number of subjects: 0
Study 36703196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36703250 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (8-session emotion and self-regulation group intervention with daily app-based prompts)
Number of subjects: 120
Study 36703250 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (received 5 months later)
Number of subjects: 120
Study 36704479 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Fumai lyophilized injection (YQFM)
Number of subjects: 1200
Study 36704634 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (20 Hz over dorsolateral prefrontal cortex bilaterally)
Number of subjects: 27
Study 36704634 — intervention group
Group type: EXPERIMENTAL
Intervention: AE (structured moderate-intensity aerobic exercise for 5 days/week over 2 weeks)
Number of subjects: 27
Study 36704634 — intervention group
Group type: COMPARATOR
Intervention: Control (only pharmacological therapy)
Number of subjects: 27
Study 36704737 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP program (20-session individual intervention based on Compassion Focused Therapy)
Number of subjects: 0
Study 36704737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36704757 — intervention group
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) intervention delivered weekly for 4 weeks
Number of subjects: 43
Study 36704757 — intervention group
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) intervention
Number of subjects: 43
Study 36704795 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient-containing supplement including zinc, taken preconception and throughout pregnancy until birth.
Number of subjects: 0
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative myocardial infarction/injury (PMI)
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACEs)
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-cardiac PMI
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 myocardial infarction (T1MI)
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachyarrhythmia
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heart failure (AHF)
Number of subjects: 7754
Study 36705050 — intervention group
Group type: EXPERIMENTAL
Intervention: Likely type 2 myocardial infarction (lT2MI)
Number of subjects: 7754
Study 36705050 — intervention group
Group type: COMPARATOR
Intervention: No PMI
Number of subjects: 7754
Study 36705266 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23
Number of subjects: 128
Study 36705266 — intervention group
Group type: COMPARATOR
Intervention: PPSV23 alone
Number of subjects: 128
Study 36705268 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-positive pre-Delta cohort
Number of subjects: 2402
Study 36705268 — intervention group
Group type: COMPARATOR
Intervention: COVID-negative participants
Number of subjects: 2402
Study 36705268 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-positive participants across variants
Number of subjects: 2402
Study 36705404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccination
Number of subjects: 57
Study 36705404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccination after influenza vaccination
Number of subjects: 57
Study 36705433 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment for comorbid posttraumatic stress and substance use disorders
Number of subjects: 0
Study 36705474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PPD immunotherapy for the largest wart (Group A)
Number of subjects: 50
Study 36705474 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy for all warts plus intralesional PPD for the largest wart (Group B)
Number of subjects: 50
Study 36705526 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks with enzalutamide 160 mg once daily and ADT
Number of subjects: 1232
Study 36705526 — intervention group
Group type: COMPARATOR
Intervention: placebo every 3 weeks with enzalutamide 160 mg once daily and ADT
Number of subjects: 1232
Study 36705559 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicompartmental signal model for whole-body diffusion-weighted imaging (DWI)
Number of subjects: 0
Study 36705566 — intervention group
Group type: EXPERIMENTAL
Intervention: 145 mg/day of nanocrystallized fenofibrate
Number of subjects: 15
Study 36705566 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 15
Study 36705644 — intervention group
Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel (ide-cel)
Number of subjects: 0
Study 36705702 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics+placebo
Number of subjects: 439
Study 36705702 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics+fish oil
Number of subjects: 439
Study 36705702 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (combined probiotics+placebo and probiotics+fish oil)
Number of subjects: 439
Study 36705702 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (combined fish oil+placebo and probiotics+fish oil)
Number of subjects: 439
Study 36705710 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric orthokeratology
Number of subjects: 30
Study 36705710 — intervention group
Group type: COMPARATOR
Intervention: Soft toric multifocal lenses
Number of subjects: 30
Study 36705923 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus interferon alfa
Number of subjects: 199
Study 36705923 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide
Number of subjects: 199
Study 36705924 — intervention group
Group type: EXPERIMENTAL
Intervention: SGM-101 (10 mg) infused up to 5 days before index operation.
Number of subjects: 10
Study 36705924 — intervention group
Group type: COMPARATOR
Intervention: Control group (CEACAM5-positive tumors).
Number of subjects: 10
Study 36705941 — intervention group
Group type: COMPARATOR
Intervention: Sodium phenylbutyrate-taurursodiol (PB-TURSO), a combination of 3 g of PB and 1 g of TURSO given twice daily.
Number of subjects: 0